Complement factor B targeting small interfering RNA - Argo Biopharma
Alternative Names: CFB siRNALatest Information Update: 21 Aug 2025
At a glance
- Originator Argo Biopharma
- Class Small interfering RNA
- Mechanism of Action Complement factor B expression modulators; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I IgA nephropathy; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 21 Aug 2025 Phase-I clinical trials in IgA nephropathy (Parenteral) before August 2025 (Argo Biopharma pipeline, August 2025)
- 21 Aug 2025 Phase-I clinical trials in Myasthenia gravis before August 2025 (Parenteral) (Argo Biopharma pipeline, August 2025)
- 21 Aug 2025 Phase-I clinical trials in Paroxysmal nocturnal haemoglobinuria (Parenteral) before August 2025 (Parenteral) (Argo Biopharma pipeline, August 2025)